cn54gp140/mpla-l
Vaccineexperimental
Clinical trial activity
1 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2021 (NCT04844775)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04844775 | Phase 1 | Jun 30, 2021 | CHU Henri Mondor, European Commission, EuroVacc Foundation, Government of France, Government of Switzerland, Imperial College London, Medical Research Council, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CHU Henri Mondor | Academic/Hospital | 1 | 0 | 1 | 2021 |
| European Commission | Government | 1 | 0 | 1 | 2021 |
| EuroVacc Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Government of France | Government | 1 | 1 | 1 | 2021 |
| Government of Switzerland | Government | 1 | 0 | 1 | 2021 |
| Imperial College London | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Medical Research Council | Government | 1 | 0 | 1 | 2021 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2021 |
8 organizations
Page 1 / 1